SecBot SecBot
SECBOTREPLAY Home › Report › ORIC

ORIC · ORIC Pharmaceuticals filed an 8-K reporting the stockholder-approved…

Oric Pharmaceuticals, Inc. · 8-K filed Jun 22, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Jun 22, 2026 at 16:05 ET

ORIC Pharmaceuticals filed an 8-K reporting the stockholder-approved amendment and restatement of its 2020 Equity Incentive Plan at the June 18, 2026 annual meeting. Key changes include reducing the annual evergreen increase from 5% to 4% of outstanding shares (removing the 2,656,500-share cap) and eliminating the ability to implement an exchange program. The filing also reports the re-election of directors Jacob M. Chacko, M.D. and Mardi C. Dier, ratification of KPMG as auditor, and an advisory vote supporting annual say-on-pay frequency. This is a routine governance filing with no material financial impact.

  • Stockholders approved the amended and restated 2020 Equity Incentive Plan with 61,228,918 votes for, 27,264,875 against, and 1,212,463 abstentions.
  • The annual evergreen provision was amended to reduce the annual increase from 5% to 4% of outstanding shares, removing the prior fixed cap of 2,656,500 shares.
  • The plan now caps incentive stock option issuance at 10,000,000 shares.
  • The administrator's ability to implement an exchange program (cancelling/re-pricing underwater options) was eliminated.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access